Monthly Prescribing Reference

Zoryve Cream 0.15% Approved for Atopic Dermatitis

Credit: Arcutis. The approval was supported by data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.15% for ...
American Academy of Dermatology

American Academy of Dermatology Issues First-Ever Pediatric Atopic Dermatitis Guidelines, Highlighting Prevention Strategies and Effective Treatments

The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric ...

Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the 10 Overlooked Growth Stocks to Buy Now. Arcutis Biotherapeutics Inc.
Monthly Prescribing Reference

Zoryve Cream 0.05% Approved for Atopic Dermatitis in 2- to 5-Year-Olds

Credit: Acrutis. Zoryve cream 0.05% is a once-daily, steroid-free cream for atopic dermatitis in patients aged 2 to 5 years. Zoryve cream 0.05% is expected to be available by the end of October 2025.

Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis

VTAMA was the only steroid-free topical AAD found supported by high certainty of evidence across all severities in children 2 years and older with AD.
Healio

Zoryve cream 0.15% improves atopic dermatitis across diverse skin types

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. More than a quarter of patients achieved a clear or ...
Healio

Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AD affected more than 35% body surface area of study ...
Business Insider

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough Award” ZORYVE is the number one prescribed branded topical ...
Business Wire

Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 ...

- 80.7% (574/711) of patients achieved EASI75 (at least a 75% reduction in disease burden) in an integrated analysis of all the ADORING Program studies - - 77.9% (218/280) of patients ≥12 years old ...

8 perioral dermatitis treatments I swear by as a beauty editor

When my skin is angry and my perioral dermatitis is at its worst, I recommend Avène’s cicalfate+ restorative protective cream ...
Business Wire

Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...

5 Overlooked Growth Stocks to Buy Now

In this article, we will list the 5 Overlooked Growth Stocks to Buy Now. Please visit 10 Overlooked Growth Stocks to Buy Now ...